We had previously scheduled the start on August 22, 2022, but due to various circumstances, we have decided to delay the launching of the testing.
We apologize for any inconvenience this may cause to those who have expressed interest and expectations, and we appreciate your patience.<\/p>\n\n\n\n
We are pleased to announce the start of high-precision NIPT<\/a> in cooperation with NIPD genetics in the Republic of Cyprus (hereinafter referred to as NIPD). This will be available in the following clinics: Tokyo, Omiya, Yokohama, and Nagoya. We will be sending the specimens to NIPD and they’ll be sending the results back to us. The project is scheduled to be completed around August 2022, and the domestic testing is scheduled to start around October 2022. In addition to the conventional testing, it will be able to detect four microdeletion syndromes and 100 severe recessive genetic disorders. Microdeletion syndrome can be detected only with a maternal blood sample, while recessive genetic disorders<\/a> require a blood sample from the mother and a cheek mucosa (buccal mucosa) specimen from the father.<\/p>\n\n\n\n If the test is positive, the patient can have an amniotic fluid test performed by an obstetrician\/gynecologist of Hiro clinic NIPT<\/a> and can be sent to Cyprus for a definitive diagnosis as well. Microdeletion syndrome is an incidental condition and is known to occur regardless of maternal age. In addition, the same amniotic fluid test can be used to make a definitive diagnosis in 100 recessive genetic disorders<\/a>.<\/p>\n\n\n\n![\"\"](\"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-content\/uploads\/2022\/07\/000010380.gif\")
<\/figure>\n\n\n\n